Efficacy and Safety of Macitentan Across Pulmonary Hypertension Phenotypes: A Systematic Review and Meta-analysis
This systematic review and meta-analysis of 14 studies indicates that macitentan therapy across pulmonary hypertension phenotypes improves specific hemodynamic parameters and reduces mortality, but does not significantly enhance exercise capacity or mean pulmonary arterial pressure, while being associated with higher risks of anemia, peripheral edema, and treatment discontinuation.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
The human heart is a pump that sends blood to the lungs to pick up oxygen, and then sends that oxygen-rich blood to the rest of the body. In a healthy person, the vessels in the lungs are wide and flexible, allowing blood to flow through them with very little resistance. Pulmonary hypertension is a condition where these vessels become stiff or narrowed, forcing the heart to work much harder to push blood through. Over time, this extra strain can weaken the heart muscle, leading to serious illness. Doctors treat this condition with medications designed to relax the blood vessels and lower the pressure. One such medication is macitentan, a drug that blocks specific chemical signals that cause the vessels to tighten. While this drug is well-known for helping patients with a specific type of lung vessel disease, researchers have wondered if it works just as well for other types of lung pressure problems, and whether the benefits are consistent across all patients.
A team of researchers set out to answer these questions by gathering and analyzing data from fourteen different studies involving more than 5,000 people. They looked at patients with various forms of high lung pressure, including those caused by blood clots, heart disease, and the classic form of the lung vessel disease. The scientists compared patients who took macitentan against those who took a placebo or other standard treatments. Their goal was to see if the drug improved the physical ability of the patients, such as how far they could walk, and whether it improved the actual pressure and flow within the lungs. They also carefully tracked how often patients experienced side effects or had to stop taking the medication.
The analysis revealed a clear picture of how the drug affects the body's internal plumbing. The researchers found that macitentan significantly lowered the resistance in the lung vessels, making it easier for blood to flow through. This reduction in resistance was accompanied by a measurable increase in the amount of blood the heart pumped out with each beat. These are important signs that the drug is successfully relaxing the vessels and helping the heart work more efficiently. However, when the researchers looked at how far patients could walk in six minutes, a common test of physical fitness, the results were different. The drug did not lead to a statistically significant improvement in walking distance compared to the control groups. Similarly, the average pressure in the main artery of the lung did not drop enough to be considered a clear success across all the studies.
The safety profile of the drug showed a mix of positive and negative outcomes. The analysis suggested that patients taking macitentan had a lower risk of dying compared to those in the control groups, a finding that was particularly strong in patients with the classic form of the lung vessel disease. However, the drug also carried a higher risk of specific side effects. Patients were more likely to develop anemia, a condition where the blood has fewer red blood cells than normal, and they were more likely to experience swelling in their legs and feet. Because of these side effects, more patients in the macitentan group had to stop taking the medication than in the control groups.
The researchers noted that the drug's effects were not the same for every type of patient. The benefits in lowering vessel resistance and improving blood flow were consistent across different groups, but the ability to translate these internal improvements into better physical performance varied. For instance, the drug showed promise in patients with blood clots in the lungs, but the data for patients with high lung pressure caused by heart disease was less clear. The study also highlighted that the dose of the drug matters; in one large trial where a much higher dose was tested, the drug failed to improve walking distance and the study was stopped early. This suggests that the relationship between the amount of drug given and the results is complex and depends heavily on the specific type of lung disease the patient has.
Ultimately, the study concludes that macitentan is a powerful tool for improving the internal mechanics of the lungs and the heart's pumping ability, but it does not guarantee that a patient will feel stronger or be able to walk further. The decision to use this medication requires a careful balance between the clear benefits of reduced vessel resistance and the increased risk of side effects like swelling and low blood counts. The findings suggest that doctors should not treat all forms of high lung pressure as the same condition. Instead, they must consider the specific cause of the patient's illness and the individual's response to the drug, recognizing that a medication that helps the heart pump better does not always translate to a better day-to-day life for every patient.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.